Emboline Raises $20M in Growth Capital to Advance Embolic Protection System

During a TAVR procedure the room is focused on one thing. Precision. Timing. Millimeters that decide whether a failing valve becomes a second chance. But beneath the choreography of wires, catheters, and imaging screens, there is another battle happening quietly in the bloodstream. Tiny fragments of debris can break loose and drift toward the brain. Small particles. Massive consequences. Emboline built a company around intercepting that moment before it turns into something worse.

This week Emboline secured $20M in growth capital from Trinity Capital Inc. to push the Emboliner Embolic Protection System closer to widespread commercialization. A strong vote of confidence in a company built around one idea that sounds simple until you try to engineer it. Catch the debris. Protect the brain. Do it without slowing down the procedure that saves the patient in the first place.

Congratulations to Founder Amir Belson, MD, President and CEO Scott Russell, CFO Mark Caires, SVP Clinical and Medical Affairs Laura Brenton, and VP Product Development Matt Davis. Building medtech is not a highlight reel. It is years of engineering discipline, regulatory patience, and clinical evidence stacking brick by brick until the structure finally stands tall enough for capital to walk in the room.

The Emboliner system operates like a precision safety net inside the aorta. A cylindrical nitinol mesh designed to capture embolic debris that might otherwise travel to the brain or downstream into the body. The device includes an expandable access port so physicians can perform the TAVR procedure while the protection system quietly does its job. No extra access site. No procedural chaos. Just smart engineering sitting exactly where it needs to be.

Clinical work tells the early chapters of the story. In the SafePass 2 study the Emboliner system captured roughly 5x the debris of commercial devices. Not marketing poetry. Data. The kind that makes physicians lean in and investors start asking bigger questions about what full body embolic protection could mean as TAVR procedures continue expanding across the United States and Europe.

Enrollment has been completed in a pivotal U.S. IDE trial designed to support regulatory submission. That milestone places Emboline in the transition zone between clinical promise and commercial reality. The $20M from Trinity Capital Inc. arrives right in that window where engineering, clinical validation, and market timing start moving in rhythm.

Quiet innovations often travel the longest distance in medicine. Emboline built a system designed to catch what nobody wants traveling through the bloodstream. And when a company turns an invisible risk into a solvable engineering problem, people start paying attention.